专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016185026A1 METHODS AND PHARMACEUTICAL COMPOSITION FOR MODULATION POLARIZATION AND ACTIVATION OF MACROPHAGES 审中-公开
标题翻译：用于调制极化和激活的方法和药物组合物
公开(公告)号：WO2016185026A1
公开(公告)日：2016-11-24
申请号：PCT/EP2016/061463
申请日：2016-05-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS SUD , INSTITUT GUSTAVE ROUSSY , INSTITUT PASTEUR
发明人： PERFETTINI, Jean-Luc , PAOLETTI, Audrey , GOUGEON, Marie-Lise
IPC分类号： A61K31/00 , A61K38/00 , A61K48/00 , A61P35/00 , A61P31/00 , A61P37/00
CPC分类号： A61K31/7072 , A61K31/00 , A61K31/7034 , A61K31/7076 , A61K31/7084 , A61K38/177 , A61K48/00 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage M1/M2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of P2Y2 receptor agonists or antagonists.
摘要翻译：本发明涉及用于调节极化和巨噬细胞活化的方法和药物组合物。特别地，本发明涉及在有需要的受试者中调节巨噬细胞M1 / M2极化的方法，包括向受试者施用治疗有效量的P2Y2受体激动剂或拮抗剂。

2. 发明申请

WO2016092041A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS 审中-公开
标题翻译：用于治疗人免疫缺陷病毒1型（HIV-1）感染的方法和药物组合物
公开(公告)号：WO2016092041A1
公开(公告)日：2016-06-16
申请号：PCT/EP2015/079310
申请日：2015-12-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE PARIS-SUD , INSTITUT GUSTAVE ROUSSY , UNIVERSITÉ PARIS DESCARTES , UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) , INSTITUT PASTEUR , ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE IRCCS LAZZARO SPALLANZANI , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
发明人： KROEMER, Guido , PERFETTINI, Jean-Luc , GOUGEON, Marie-Lise , ALLOUCH, Awatef , PIACENTINI, Mauro
IPC分类号： C12N15/113 , A61K31/7088
CPC分类号： C12N15/113 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/5517 , A61K31/683 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N15/1132 , C12N2310/14 , C12N2320/31 , C12Q1/18 , A61K2300/00
摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.
摘要翻译：本发明提供了用于治疗1型（HIV-1）感染的人类免疫缺陷病毒的方法和药物组合物。特别地，本发明涉及在有需要的受试者中治疗HIV-1感染的方法，包括给予受试者治疗有效量的SGT1活性抑制剂或表达。

3. 发明申请

WO2021224569A1 SYSTÈME DE DIALYSE POUR LE TRAITEMENT DU SEPSIS. 审中-公开
公开(公告)号：WO2021224569A1
公开(公告)日：2021-11-11
申请号：PCT/FR2021/050750
申请日：2021-04-30
申请人： MEXBRAIN , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT GUSTAVE ROUSSY , VETAGRO-SUP INSTITUT D'ENSEIGNEMENT SUPÉRIEUR ET DE RECHERCHE
发明人： NATUZZI, Marco , BRICHART, Thomas , ROSSETTI, Fabien , MARTINI, Matteo , LUX, François , TILLEMENT, Olivier , PERFETTINI, Jean-Luc , LOUZIER, Vanessa , BONNET-GARIN, Jeanne-Marie , AYOUB, Jean-Yves
IPC分类号： A61M1/16 , A61M1/34 , A61M1/36
摘要： La présente invention concerne le domaine des dispositifs médicaux, plus particulièrement le domaine des dispositifs permettant d'extraire des molécules circulantes du sang d'un mammifère, et leurs utilisations thérapeutiques notamment dans le traitement du sepsis, du syndrome de libération de cytokines et/ou de toute autre forme de réponse inflammatoire systémique ou choc cytokinique, causés par des infections bactériennes, parasitaires, fongiques ou virales, en particulier causés par une infection virale, par exemple les coronavirus à tropisme respiratoire humain.

4. 发明申请

WO2022229575A1 CARDIOPROTECTION PAR INDUCTION D'AUTOPHAGIE ET REPROGRAMMATION METABOLIQUE 审中-公开
公开(公告)号：WO2022229575A1
公开(公告)日：2022-11-03
申请号：PCT/FR2022/050829
申请日：2022-04-29
申请人： UNIVERSITE PARIS-SACLAY , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES , INSTITUT GUSTAVE ROUSSY
发明人： BRENNER, Catherine , TARAN, Frédéric , CINTRAT, Jean-Christophe , PERFETTINI, Jean-Luc
IPC分类号： A61K31/4174 , A61K31/15 , A61K31/513 , A61P35/00 , A61P9/00 , A61P39/00 , A61K45/06
摘要： L'invention concerne des composés capables d'induire une autophagie et la reprogrammation métabolique et leur utilisation en tant que cardioprotecteurs, notamment dans le cadre d'une thérapie anti-cancéreuse.

5. 发明申请

WO2021053173A1 METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION 审中-公开
公开(公告)号：WO2021053173A1
公开(公告)日：2021-03-25
申请号：PCT/EP2020/076157
申请日：2020-09-18
申请人： NH THERAGUIX , INSTITUT GUSTAVE ROUSSY , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE PARIS-SACLAY
发明人： ALLOUCH, Awatef , DEUTSCH, Eric , PERFETTINI, Jean-Luc , LUX, François , TILLEMENT, Olivier
IPC分类号： A61K41/00 , A61K47/69 , A61K49/18 , A61P35/00 , A61P1/16 , A61P9/10 , A61P11/00 , A61P37/08 , A61K39/00 , A61N5/10
摘要： The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

6. 发明申请

WO2019008040A1 METHODS FOR TREATING TUMORS 审中-公开
公开(公告)号：WO2019008040A1
公开(公告)日：2019-01-10
申请号：PCT/EP2018/068099
申请日：2018-07-04
申请人： NH THERAGUIX , UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , INSTITUT GUSTAVE ROUSSY
发明人： LUX, François , TILLEMENT, Olivier , PERFETTINI, Jean-Luc , DEUTSCH, Eric , LAW, Frédéric , ALLOUCH, Awatef
IPC分类号： A61K41/00
摘要： The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

7. 发明申请

WO2005059554A1 PUMA, PHOSPHORYLATED P53 AND P38 MAP KINASE AS MARKERS FOR HIV-1-INDUCED APOPTOSIS IN CIRCULATING T CELLS OF INFECTED PATIENT 审中-公开
标题翻译： PUMA，磷酸化P53和P38 MAP激酶作为感染性患者循环T细胞中HIV-1诱导的病毒标记
公开(公告)号：WO2005059554A1
公开(公告)日：2005-06-30
申请号：PCT/IB2004/004331
申请日：2004-12-10
申请人： INSTITUT GUSTAVE-ROUSSY , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE (INMI) , UNIVERSITE PARIS SUD , KROEMER, Guido , PERFETTINI, Jean-Luc , PIACENTINI, Mauro
发明人： KROEMER, Guido , PERFETTINI, Jean-Luc , PIACENTINI, Mauro
IPC分类号： G01N33/569
CPC分类号： G01N33/56988 , G01N2500/00 , G01N2510/00 , G01N2800/52
摘要： The subject matter of the present invention relates to an in vitro method for the screening of anti-HIV compounds, or for predicting the progression of HIV related diseases, or for determining the efficiency of an anti-HIV-1 treatment based on the measuring of the expression level of Puma and, optionally, on the measuring of the phosphorylated p53 and/or the p38 MAP kinase protein level in circulating white blood cells of a sample from a HIV infected patient, particularly HIV-1. The invention further comprises a method for the diagnostic of HIV infection in a patient and kits for performing these methods.
摘要翻译：本发明的主题涉及用于筛选抗HIV化合物的体外方法，或用于预测HIV相关疾病的进展，或者基于测量的HIV-1治疗的效力来确定 Puma的表达水平，以及任选地测量来自HIV感染患者，特别是HIV-1的样品的循环白细胞中的磷酸化p53和/或p38MAP激酶蛋白水平。本发明还包括用于诊断患者中HIV感染的方法和用于执行这些方法的试剂盒。

8. 发明申请

WO2021245107A2 MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM 审中-公开
公开(公告)号：WO2021245107A2
公开(公告)日：2021-12-09
申请号：PCT/EP2021/064718
申请日：2021-06-01
申请人： INSTITUT GUSTAVE ROUSSY
发明人： PERFETTINI, Jean-Luc , LECUYER, Deborah , TANNOUS, Désirée , ALLOUCH, Awatef , DELELIS, Olivier , SUBRA, Frederic
IPC分类号： A61K31/7084 , A61K31/675 , A61K31/7072 , A61P11/00 , A61P31/14 , A61K45/06
摘要： The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

9. 发明申请

WO2018050928A1 NOX2 AS A BIOMARKER OF RADIOTHERAPY EFFICIENCY IN CANCER PATIENTS 审中-公开
标题翻译： NOX2作为癌症患者放射治疗效果的生物标志物
公开(公告)号：WO2018050928A1
公开(公告)日：2018-03-22
申请号：PCT/EP2017/073677
申请日：2017-09-19
申请人： INSTITUT GUSTAVE-ROUSSY
发明人： PERFETTINI, Jean-Luc , DEUTSCH, Eric , ALLOUCH, Awatef
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57419 , G01N2800/52
摘要： Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.
摘要翻译：虽然肿瘤相关巨噬细胞已广泛研究了放疗反应的控制，但涉及电离辐射介导的巨噬细胞活化的分子机制仍然难以捉摸。在此，本发明人表明，电离辐射诱导干扰素调节因子5（IRF5）的表达，从而促进巨噬细胞活化为促炎症表型。他们揭示，激活共济失调毛细血管扩张突变（ATM）激酶是电离辐射引起的巨噬细胞激活所必需的，而且在γ-干扰素，脂多糖或化学治疗剂（如顺铂）治疗后用于巨噬细胞重编程需要，强调事实上激酶ATM在巨噬细胞表型转换为促炎症表型过程中起着核心作用。他们进一步证明NADPH氧化酶2（NOX2）依赖性ROS产生在ATM激活的上游，并且在此过程中是必不可少的。他们还报告说，缺氧条件和这种信号通路的任何成分（NOX2，ROS和ATM）的抑制都会损害巨噬细胞的促炎激活，并预测局部晚期直肠癌术前放疗的肿瘤反应差。总之，这些结果确定了涉及巨噬细胞活化的新信号通路，其可通过重新编程肿瘤浸润巨噬细胞来提高放射疗法的有效性。

10. 发明申请

WO2021069686A1 NOVEL THERAPEUTIC COMBINATIONS COMPRISING DERIVATIVES OF OXAZAPHOSPHORINES FOR THE TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2021069686A1
公开(公告)日：2021-04-15
申请号：PCT/EP2020/078458
申请日：2020-10-09
申请人： INSTITUT GUSTAVE ROUSSY
发明人： PACI, Angelo , CHAPUT, Nathalie , PERFETTINI, Jean-Luc , DELAHOUSSE, Julia
IPC分类号： A61K31/185 , A61K31/664 , A61K45/00 , A61P35/00 , A61P37/02 , A61K45/06 , A61K39/395 , C07K16/28
摘要： The present invention relates to novel therapeutic combinations comprising an oxazaphosphorine derivative and an immune checkpoint modulator for the treatment or the prevention of cancers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式